首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1902511

神经生物标记市场规模、份额及成长分析（按类型、应用、最终用户和地区划分）－2026-2033年产业预测

Neurological Biomarkers Market Size, Share, and Growth Analysis, By Type (Genomic, Proteomic), By Application (Alzheimer's Disease, Parkinson's Disease), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，神经生物标记市场规模将达到 79.1 亿美元，到 2025 年将达到 89.9 亿美元，到 2033 年将达到 249.2 亿美元，在预测期（2026-2033 年）内，复合年增长率为 13.6%。

神经生物标记在多种疾病的诊断中至关重要，包括自闭症、帕金森氏症和忧郁症。它们涵盖代谢体学、影像学、基因组学和蛋白质组学，有助于扩展治疗方法选择、实现早期诊断和非侵入性检测。这些生物标记为製药公司提供宝贵的见解，进而改善临床试验决策，进一步推动市场需求。随着个人化医疗的进步，神经退化性疾病的神经生物标记研究正在迅速发展，并推动生物製药产业从研发转向商业化。支持健康差异研究的机构增加的资金投入有望促进市场扩张，凸显了这些生物标记在推动产业诊断和治疗领域创新与成长方面的重要作用。

全球神经生物标记市场按类型、应用、最终用户和地区进行细分。按类型划分，可分为基因组学、蛋白质组学、代谢体学、影像学和其他。按应用划分，可分为阿兹海默症、帕金森氏症、多发性硬化症、泛自闭症障碍和其他。依最终使用者划分，可分为医院/医院检查室、独立临床诊断中心、研究机构和其他。依地区划分，可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

神经生物标记市场驱动因素

生物标记在指示各种健康状况和疾病方面发挥关键作用。癌症发生是一个复杂的多步骤过程，涉及众多分子通路，使得癌症的诊断、预后和治疗极为复杂。因此，仅依赖单一生物标记是不够的，因为每种癌症类型都具有独特的分子特征。新生物标记的发现有助于开发针对癌症相关特定失调的标靶治疗。随着癌症发病率的持续上升，生物标记研究日益受到关注，预计这将显着推动神经生物标记市场的成长。

限制神经生物标记市场的因素

神经生物标记市场面临阻碍成长的重大挑战，主要原因在于生物标记研究的复杂性。整合快速发展且多样化的资料集构成了巨大的障碍，因为生物标记资讯通常来自多个平台，包括传统血液检测、次世代定序和萤光杂合反应。此外，缺乏标准化的报告方法，特别是针对次世代定序检测，使得采用不同调查方法的机构之间难以进行资料解读和总结。另外，不同种族、民族和经济群体在生物标记检测方面的差异进一步限制了数据的可及性和整体性。

神经生物标记市场趋势

由于大量资金涌入促进研发，神经生物标记市场正经历显着成长。来自各组织和政府机构的投资不断增加，推动了对阿兹海默症和脑衰老等疾病的创新研究。这些资金有助于寻找具有提高诊断准确性和治疗效果潜力的新型生物标记。尤其值得一提的是，旨在消除神经退化性疾病健康差异的努力正日益受到关注，这提升了生物标记在临床应用中的重要性。这一趋势不仅加速了研究进展，也拓展了神经生物标记领域的市场格局。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Quanterix Corporation
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
QIAGEN NV
Bio-Rad Laboratories, Inc.
Merck KGaA
F. Hoffmann-La Roche Ltd
Bio-Techne Corporation
Alector Inc.
Banyan Biomarkers, Inc.
Charles River Laboratories International, Inc.
Cisbio
C2N Diagnostics
ImmunArray
Euroimmun AG
Cerebrospinal Fluid Diagnostics
Abbott Laboratories

简介目录

Product Code: SQMIG35A2399

Neurological Biomarkers Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.99 Billion in 2025 to USD 24.92 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

Neurological biomarkers are pivotal in diagnosing various conditions, including autism, Parkinson's disease, and depression. They encompass metabolomics, imaging, genomics, and proteomics, facilitating enhanced treatment options, earlier diagnoses, and non-invasive testing methods. The demand for these biomarkers is further propelled by the valuable insights they provide for pharmaceutical companies, improving clinical trial decision-making. As personalized medicine evolves, research in neurological biomarkers for neurodegenerative diseases is rapidly advancing, transforming the biopharmaceutical landscape from R&D to commercial sectors. Increased funding from organizations supporting health disparity research is likely to foster market expansion, highlighting the critical role of these biomarkers in driving innovation and growth across diagnostics and therapeutic domains within the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segments Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

Biomarkers play a crucial role in indicating various health conditions and diseases. The intricate multistage process of carcinogenesis involves numerous molecular pathways, making cancer diagnosis, prognosis, and treatment highly complex. Consequently, relying on a single biomarker is inadequate, as each type of cancer possesses a distinct molecular profile. The discovery of new biomarkers facilitates the creation of targeted therapies that address specific dysregulations associated with cancer. As the incidence of cancer continues to rise, it drives an increased focus on biomarker research, which is anticipated to significantly enhance the growth of the neurological biomarkers market.

Restraints in the Neurological Biomarkers Market

The Neurological Biomarkers market faces significant challenges that hinder its growth, primarily due to the complexities involved in biomarker research. The integration of diverse and rapidly evolving data sets poses a substantial hurdle, as biomarker information is often sourced from a multitude of platforms such as traditional blood tests, next-generation sequencing, and fluorescence in situ hybridization. Additionally, the absence of standardized reporting practices, particularly for next-generation sequencing tests, complicates data interpretation and aggregation among organizations employing various methodologies. Furthermore, disparities in biomarker testing across different racial, ethnic, and economic populations further limit data accessibility and comprehensiveness.

Market Trends of the Neurological Biomarkers Market

The neurological biomarkers market is experiencing significant growth driven by an influx of funding aimed at advancing research and development. Increased investments from various organizations and governmental bodies are fostering innovative studies focused on conditions like Alzheimer's disease and brain aging. These funds are facilitating explorations into novel biomarkers that can enhance diagnostic accuracy and treatment efficacy. In particular, initiatives targeting health disparities in neurodegenerative conditions are gaining traction, thereby elevating the relevance of biomarkers in clinical settings. As a result, this trend is not only accelerating the pace of research but also enhancing market potential within the neurological biomarker landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pipeline Analysis
Penetration and Growth Prospects Analysis
PESTEL Analysis
Patent Analysis

Neurological Biomarkers Market, By Type

Market Overview
Genomic
Proteomic
Metabolomic
Imaging
Others

Neurological Biomarkers Market, By Application

Market Overview
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others

Neurological Biomarkers Market, By End User

Market Overview
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations and Others

Neurological Biomarkers Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Quanterix Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Techne Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alector Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Banyan Biomarkers, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cisbio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
C2N Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunArray
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Euroimmun AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cerebrospinal Fluid Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments